Fab Antibody Fragment Titer Improvement 

Fab Antibody Fragment Titer Improvement 

Challenge A partner was developing a Fab fragment to quickly neutralize a therapeutic substrate Their E. coli platform generated low Fab titer and meaningful supply was needed for clinical development A cost effective process required titers >2 g/L Solution...
Multimeric VHH Nanobody Expression 

Multimeric VHH Nanobody Expression 

BACKGROUND VHH single domain antibodies readily express in the Pfenex Expression Technology® Expression and enrichment of a variety of VHH specificities facilitated early drug development Challenge Assess VHH concatemer expression and linker strategies to enhance...
Recombinant Erwinia Asparaginase Production

Recombinant Erwinia Asparaginase Production

BACKGROUND Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. Lymphoblastic lymphoma (LBL) is a rare, fast-growing, aggressive subtype of non- Hodgkin’s lymphoma most often seen in teenagers and young adults. Asparaginases are a key...